By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Altor BioScience Corporation 

2810 North Commerce Parkway

Miramar  Florida  33025-3958  U.S.A.
Phone: 954-443-8600 Fax: 954-443-8610


Company News
Altor BioScience Corporation Announces National Cancer Institute Phase II SBIR Grant Award And Publication Supporting Ongoing Clinical Trial Of IL-15 Super Agonist ALT-803 In Combination With Anti-CD20 Antibody Therapy For Relapsed / Refractory Non-Hodgkin Lymphoma 10/6/2015 10:58:22 AM
ASCO15: Altor BioScience Corporation Announces Upcoming Data Presentation On Efficacy And Safety Of ALT-801 For Advanced Bladder Cancer At 2015 ASCO Annual Meeting 5/28/2015 11:13:26 AM
Altor BioScience Corporation Announces The Appointment Of Kevin Taylor As Chief Business Officer 1/6/2015 11:49:14 AM
Altor BioScience Corporation Initiates Clinical Development Of Its Novel IL-15 Super Agonist ALT-803 For Relapsed / Refractory Multiple Myeloma Supported By A Newly Awarded Phase 2 SBIR Grant From National Cancer Institute 11/4/2014 10:22:56 AM
Shenzhen Beike Biotechnology Co. Ltd., Altor BioScience Corporation Strike $200 Million Cancer Deal 9/10/2014 10:48:59 AM
Altor BioScience Corporation Awarded SBIR Phase 2 Grant By NCI For Clinical Development Of Its Novel IL-15 Super Agonist For Non-Muscle Invasive Bladder Cancer 8/19/2014 8:48:48 AM
Altor BioScience Corporation Launches Its Proprietary IL-15 Superagonist ALT-803 Into Clinical Trials Against Cancer 8/15/2013 10:49:37 AM
Altor BioScience Corporation and the Melanoma Research Alliance to Co-Support Clinical Studies of Altor’s Novel IL-15 Superagonist for Metastatic Melanoma 4/30/2012 10:25:23 AM
Florida Biologix(R) Announces Manufacturing Agreement with Altor BioScience Corporation 6/28/2011 11:34:34 AM
Altor BioScience Corporation Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI 5/23/2011 8:37:26 AM